Rezolute (RZLT) Convertible Debt (2011 - 2018)

Rezolute (RZLT) posted Convertible Debt of $5.0 million for Q4 2018, up 3.43% sequentially from $4.8 million in Q3 2018.

Analysis

Rezolute (RZLT) Convertible Debt (2011 - 2018) Analysis & Trends

Rezolute has reported Convertible Debt for 3 years, with the latest figure at $5.0 million in Q4 2018.

Quarterly Convertible Debt changed N/A year-over-year to $5.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $5.0 million (changed N/A YoY) and the FY2011 annual result came in at $54958.0, changed N/A from the prior year.
Convertible Debt advanced to $5.0 million in Q4 2018 per RZLT's latest filing, from $4.8 million in the prior quarter.
Over five years, Convertible Debt peaked at $5.0 million in Q4 2018 and troughed at $4.8 million in Q3 2018.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.51 Bn	130.66 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.24 Bn	77.25 Bn	3.93 Bn
3	Argenx Se	63.46 Bn	58.28 Bn	1.37 Bn
4	Moderna	57.89 Bn	52.75 Bn	52.00 Mn
5	Revolution Medicines	44.02 Bn	44.02 Bn	-
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.49 Bn	32.19 Bn	992.69 Mn
8	Royalty Pharma	28.43 Bn	27.59 Bn	-
9	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
10	Rezolute	477.02 Mn	477.02 Mn	-

Historic Data

Download Data